Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
Appili Therapeutics to Attend BARDA Innovation Symposium 2025
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
Appili Therapeutics Announces Results of Special Meeting of Shareholders
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
Appili Therapeutics – Press Release Correction
Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025
Appili Therapeutics Announces Second Amendment to Arrangement Agreement
Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan
Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results
Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
Appili Therapeutics Presents at the 10th International Tularemia Conference
Appili Therapeutics' shares soar on FDA approval for Llikmez oral antibiotic
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate